Nanostring Tech Cmn (NSTG) 16.45 $NSTG NanoStri
Post# of 273257
Posted On: 09/03/2016 7:05:38 PM
Nanostring Tech Cmn (NSTG) 16.45 $NSTG
NanoString Technologies to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Thu Aug 25, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at two upcoming conferences in September. Presenting at the conferences will be Brad Gray, Chief Executive Officer.
NSTG: 16.45 (+0.20)
NanoString Technologies Releases Operating Results for Second Quarter of 2016
GlobeNewswire - Wed Aug 03, 3:00PM CDT
Revenue Growth of 73% Year-Over-Year Driven by Strong nCounter SPRINT Demand, Robust Consumable Pull-Through and Achievement of Biopharma Collaboration Milestones
NSTG: 16.45 (+0.20)
NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
GlobeNewswire - Thu Jun 02, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and immunotherapy using the nCounter(R) platform that will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
NSTG: 16.45 (+0.20)
Cigna Issues Positive Coverage Decision for NanoString's Prosigna(R) Breast Cancer Assay
GlobeNewswire - Thu May 26, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna(R) Breast Cancer Gene Signature Assay. Cigna and its roughly 13 million members join other payors now covering Prosigna, collectively representing more than 135 million covered lives throughout the United States.
NSTG: 16.45 (+0.20)
NanoString Technologies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 24, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Jefferies 2016 Healthcare Conference in New York, NY.
NSTG: 16.45 (+0.20)
Aetna Issues Positive Coverage Decision for NanoString's Prosigna(R) Breast Cancer Assay
GlobeNewswire - Mon May 09, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Aetna has added the Prosigna(R) Breast Cancer Gene Signature Assay to its Tumor Markers Clinical Policy Bulletin. Aetna and its more than 19 million members join other payors now covering Prosigna, collectively representing approximately 125 million covered lives throughout the United States.
NSTG: 16.45 (+0.20)
NanoString Technologies Releases Operating Results for First Quarter of 2016
GlobeNewswire - Thu May 05, 3:00PM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter ended March 31, 2016.
NSTG: 16.45 (+0.20)
NanoString Technologies to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed Apr 27, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV.
NSTG: 16.45 (+0.20)
NanoString Technologies Unveils New nCounter Vantage(TM) Assays to Power Cancer Research With 3D Biology(TM)
GlobeNewswire - Thu Apr 14, 3:05PM CDT
nCounter Vantage Products Enable Simultaneous Analysis of DNA, RNA, and Protein to Expand Capabilities In Cancer Research, Including Immuno-Oncology
NSTG: 16.45 (+0.20)
NanoString Technologies to Release First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5, 2016
GlobeNewswire - Wed Apr 13, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2016 financial results after the close of trading on Thursday, May 5, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
NSTG: 16.45 (+0.20)
NanoString Technologies and HalioDx Enter Into Collaboration Agreement to Jointly Develop and Commercialize Novel Gene Expression Assays in Immuno-oncology
GlobeNewswire - Mon Apr 11, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and HalioDx SAS, a diagnostic company in immuno-oncology, today announced they have entered into an agreement to jointly develop and commercialize advanced gene expression assays for assessing the response to immunotherapies.
NSTG: 16.45 (+0.20)
Commit To Purchase NanoString Technologies At $10, Earn 16.3% Annualized Using Options
StockOptionsChannel.com - Tue Feb 09, 10:40AM CST
Investors considering a purchase of NanoString Technologies Inc shares, but tentative about paying the going market price of $12.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NSTG: 16.45 (+0.20)
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommends Use of Prosigna (PAM50) for Guiding Treatment Decisions in Early Stage Breast Cancer Patients
GlobeNewswire - Tue Feb 09, 6:00AM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the updated American Society of Clinical Oncology (ASCO) Clinical Practice Guideline on the appropriate use of breast tumor biomarker assay results recommends the use of the Prosigna(R) Breast Cancer Prognostic Gene Signature Assay (PAM50) to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer with known hormone receptor and HER2 status. The Prosigna assay was one of only two such assays to receive a "high" rating of evidence quality together with a "strong" recommendation.
NSTG: 16.45 (+0.20)
Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue
ACCESSWIRE - Thu Jan 28, 8:26AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), recently announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (OTCQB: PBIO). PBIO is a worldwide leader in the development and sale of pressure cycling technology (PCT)-based sample preparation systems to the life sciences research market. Under the agreement, the companies will jointly promote PBIO's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by hundreds of thousands of research laboratories worldwide. This combination of technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and dramatic revenue growth for PBIO.
NSTG: 16.45 (+0.20), A: 47.00 (+0.01), TMO: 151.18 (+0.23), NEO: 8.00 (+0.05), QGEN: 26.63 (+0.17), DHR: 81.19 (-0.25), WAT: 156.19 (+0.09)
NanoString Technologies to Present at the Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Jan 27, 3:07PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Leerink Partners 5 Annual Global Healthcare Conference in New York City.
NSTG: 16.45 (+0.20)
NanoString Technologies (NSTG) Jumps: Stock Rises 5.8%
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 7:15AM CST
NanoString Technologies, Inc. (NSTG) shares rose almost 6% in the last trading session.
NSTG: 16.45 (+0.20), ABAX: 49.50 (-0.90)
NanoString Technologies posts revenue growth of 29% to 31% for 2015 year over year
M2 - Mon Jan 11, 5:32AM CST
Life science company NanoString Technologies (NasdaqGM:NSTG) said on Friday that it expects total revenue in the range of USD61.5m to USD62.5m for the year ended 31 December 2015.
NSTG: 16.45 (+0.20)
NanoString Technologies Provides Preliminary Operational and Financial Results for 2015
GlobeNewswire - Sun Jan 10, 3:00PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended December 31, 2015.
NSTG: 16.45 (+0.20)
NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test
Marketwired - Thu Jan 07, 6:00AM CST
Medivation, Inc. (NASDAQ: MDVN) and NanoString Technologies, Inc., (NASDAQ: NSTG) today announced they have entered into a collaboration, together with Astellas Pharma Inc., to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString's nCounter(R) Dx Analysis System. Under the terms of the collaboration agreement, NanoString will be responsible for developing and validating the diagnostic test and, if the parties thereafter determine to proceed, NanoString would also be responsible for seeking regulatory approval for and commercializing the diagnostic test. NanoString is eligible to receive up to $22 million for technology access, near-term milestones and development funding, in addition to other potential undisclosed downstream payments.
MDVN: 80.85 (-0.08), NSTG: 16.45 (+0.20)
NanoString Technologies to Present at Two Upcoming Healthcare Conferences
GlobeNewswire - Thu Aug 25, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at two upcoming conferences in September. Presenting at the conferences will be Brad Gray, Chief Executive Officer.
NSTG: 16.45 (+0.20)
NanoString Technologies Releases Operating Results for Second Quarter of 2016
GlobeNewswire - Wed Aug 03, 3:00PM CDT
Revenue Growth of 73% Year-Over-Year Driven by Strong nCounter SPRINT Demand, Robust Consumable Pull-Through and Achievement of Biopharma Collaboration Milestones
NSTG: 16.45 (+0.20)
NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
GlobeNewswire - Thu Jun 02, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and immunotherapy using the nCounter(R) platform that will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
NSTG: 16.45 (+0.20)
Cigna Issues Positive Coverage Decision for NanoString's Prosigna(R) Breast Cancer Assay
GlobeNewswire - Thu May 26, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna(R) Breast Cancer Gene Signature Assay. Cigna and its roughly 13 million members join other payors now covering Prosigna, collectively representing more than 135 million covered lives throughout the United States.
NSTG: 16.45 (+0.20)
NanoString Technologies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 24, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Jefferies 2016 Healthcare Conference in New York, NY.
NSTG: 16.45 (+0.20)
Aetna Issues Positive Coverage Decision for NanoString's Prosigna(R) Breast Cancer Assay
GlobeNewswire - Mon May 09, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Aetna has added the Prosigna(R) Breast Cancer Gene Signature Assay to its Tumor Markers Clinical Policy Bulletin. Aetna and its more than 19 million members join other payors now covering Prosigna, collectively representing approximately 125 million covered lives throughout the United States.
NSTG: 16.45 (+0.20)
NanoString Technologies Releases Operating Results for First Quarter of 2016
GlobeNewswire - Thu May 05, 3:00PM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter ended March 31, 2016.
NSTG: 16.45 (+0.20)
NanoString Technologies to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Wed Apr 27, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV.
NSTG: 16.45 (+0.20)
NanoString Technologies Unveils New nCounter Vantage(TM) Assays to Power Cancer Research With 3D Biology(TM)
GlobeNewswire - Thu Apr 14, 3:05PM CDT
nCounter Vantage Products Enable Simultaneous Analysis of DNA, RNA, and Protein to Expand Capabilities In Cancer Research, Including Immuno-Oncology
NSTG: 16.45 (+0.20)
NanoString Technologies to Release First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5, 2016
GlobeNewswire - Wed Apr 13, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2016 financial results after the close of trading on Thursday, May 5, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
NSTG: 16.45 (+0.20)
NanoString Technologies and HalioDx Enter Into Collaboration Agreement to Jointly Develop and Commercialize Novel Gene Expression Assays in Immuno-oncology
GlobeNewswire - Mon Apr 11, 7:00AM CDT
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and HalioDx SAS, a diagnostic company in immuno-oncology, today announced they have entered into an agreement to jointly develop and commercialize advanced gene expression assays for assessing the response to immunotherapies.
NSTG: 16.45 (+0.20)
Commit To Purchase NanoString Technologies At $10, Earn 16.3% Annualized Using Options
StockOptionsChannel.com - Tue Feb 09, 10:40AM CST
Investors considering a purchase of NanoString Technologies Inc shares, but tentative about paying the going market price of $12.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NSTG: 16.45 (+0.20)
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommends Use of Prosigna (PAM50) for Guiding Treatment Decisions in Early Stage Breast Cancer Patients
GlobeNewswire - Tue Feb 09, 6:00AM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the updated American Society of Clinical Oncology (ASCO) Clinical Practice Guideline on the appropriate use of breast tumor biomarker assay results recommends the use of the Prosigna(R) Breast Cancer Prognostic Gene Signature Assay (PAM50) to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer with known hormone receptor and HER2 status. The Prosigna assay was one of only two such assays to receive a "high" rating of evidence quality together with a "strong" recommendation.
NSTG: 16.45 (+0.20)
Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue
ACCESSWIRE - Thu Jan 28, 8:26AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), recently announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (OTCQB: PBIO). PBIO is a worldwide leader in the development and sale of pressure cycling technology (PCT)-based sample preparation systems to the life sciences research market. Under the agreement, the companies will jointly promote PBIO's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by hundreds of thousands of research laboratories worldwide. This combination of technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and dramatic revenue growth for PBIO.
NSTG: 16.45 (+0.20), A: 47.00 (+0.01), TMO: 151.18 (+0.23), NEO: 8.00 (+0.05), QGEN: 26.63 (+0.17), DHR: 81.19 (-0.25), WAT: 156.19 (+0.09)
NanoString Technologies to Present at the Leerink Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Jan 27, 3:07PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Leerink Partners 5 Annual Global Healthcare Conference in New York City.
NSTG: 16.45 (+0.20)
NanoString Technologies (NSTG) Jumps: Stock Rises 5.8%
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 7:15AM CST
NanoString Technologies, Inc. (NSTG) shares rose almost 6% in the last trading session.
NSTG: 16.45 (+0.20), ABAX: 49.50 (-0.90)
NanoString Technologies posts revenue growth of 29% to 31% for 2015 year over year
M2 - Mon Jan 11, 5:32AM CST
Life science company NanoString Technologies (NasdaqGM:NSTG) said on Friday that it expects total revenue in the range of USD61.5m to USD62.5m for the year ended 31 December 2015.
NSTG: 16.45 (+0.20)
NanoString Technologies Provides Preliminary Operational and Financial Results for 2015
GlobeNewswire - Sun Jan 10, 3:00PM CST
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended December 31, 2015.
NSTG: 16.45 (+0.20)
NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test
Marketwired - Thu Jan 07, 6:00AM CST
Medivation, Inc. (NASDAQ: MDVN) and NanoString Technologies, Inc., (NASDAQ: NSTG) today announced they have entered into a collaboration, together with Astellas Pharma Inc., to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString's nCounter(R) Dx Analysis System. Under the terms of the collaboration agreement, NanoString will be responsible for developing and validating the diagnostic test and, if the parties thereafter determine to proceed, NanoString would also be responsible for seeking regulatory approval for and commercializing the diagnostic test. NanoString is eligible to receive up to $22 million for technology access, near-term milestones and development funding, in addition to other potential undisclosed downstream payments.
MDVN: 80.85 (-0.08), NSTG: 16.45 (+0.20)
(0)
(0)Scroll down for more posts ▼